Medpace: Continued Business Growth With Asymmetrical Payoff Opportunity

I I F ■ F Matteo Colombo Investment update Following my January '23 publication rating Medpace Holdings (NASDAQ:MEDP) a buy, the stock is +69% and has vindicated the original buy thesis presented in July '22 (I had reinstated the buy rating several times in between these two dates as well). The January publication outlined numerous investment facts that are still explicitly relevant in the investment debate today, namely: Profitability is a standout with ROICs at +33% trailing return on invested capital dri ...